Filing Flows › Zevra Therapeutics (ZVRA) › Q2 2026 › vs Q1 2026
Zevra Therapeutics (ZVRA) Q2 2026 vs Q1 2026 (quarter over quarter)
Zevra Therapeutics's revenue rose $3.4M (+10%) from $36.2M in Q1 2026 to $39.7M in Q2 2026. Operating margin 42.3% against 144.0% (-101.7 pts).
Zevra Therapeutics, Q2 2026: revenue $39.7M (+53% year over year), operating margin 42.3%, net earnings $8.8M, operating cash flow $17.0M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Operating margin | 42.3% | 144.0% | -101.7 pts |
| Net margin | 22.1% | 104.6% | -82.5 pts |
| Free cash flow margin | 42.4% | 16.9% | +25.5 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $39.7M | $36.2M | $3.4M | +10% |
| Operating profit | $16.8M | $52.1M | −$35.4M | -68% |
| Costs & expenses | $22.9M | $0 | $22.9M | — |
| Pre-tax earnings | $12.8M | $44.8M | −$32.0M | -71% |
| Other expense, net | $4.0M | $7.3M | −$3.4M | -46% |
| Net earnings | $8.8M | $37.9M | −$29.1M | -77% |
| Income tax | $4.0M | $6.9M | −$2.9M | -42% |
| Depreciation & amortization | $364K | $368K | −$4K | -1% |
| Share-based compensation | $3.0M | $3.1M | −$136K | -4% |
| Working capital & other | $4.9M | −$35.2M | $40.2M | — |
| Operating cash flow | $17.0M | $6.1M | $10.9M | +177% |
| Free cash flow (OCF − capex) | $16.8M | $6.1M | $10.7M | +175% |
| Capital expenditures | $217K | $35K | $182K | +520% |
Questions
How much did Zevra Therapeutics's revenue grow quarter over quarter in Q2 2026?
Zevra Therapeutics's revenue rose $3.4M (+10%) from $36.2M in Q1 2026 to $39.7M in Q2 2026. Operating margin 42.3% against 144.0% (-101.7 pts).